Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been assigned an average rating of “Moderate Buy” from the twelve research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $19.8750.

JSPR has been the subject of several recent research reports. Rodman & Renshaw began coverage on Jasper Therapeutics in a report on Tuesday, January 13th. They issued a “buy” rating and a $17.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Thursday, January 22nd.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JSPR. Goldman Sachs Group Inc. grew its stake in shares of Jasper Therapeutics by 6,394.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock valued at $3,196,000 after purchasing an additional 1,719,602 shares during the period. Acorn Capital Advisors LLC acquired a new stake in Jasper Therapeutics in the 3rd quarter valued at $3,291,000. Velan Capital Investment Management LP grew its position in Jasper Therapeutics by 86.1% in the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock valued at $6,206,000 after acquiring an additional 1,234,567 shares during the period. Woodline Partners LP acquired a new position in Jasper Therapeutics during the third quarter worth $2,475,000. Finally, Propel Bio Management LLC acquired a new position in Jasper Therapeutics during the third quarter worth $2,449,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Trading Up 0.7%

Shares of Jasper Therapeutics stock opened at $1.38 on Monday. Jasper Therapeutics has a 1 year low of $1.11 and a 1 year high of $7.19. The company’s fifty day simple moving average is $1.54 and its 200-day simple moving average is $2.01. The company has a market cap of $38.61 million, a price-to-earnings ratio of -0.23 and a beta of 3.08.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.